ASH 2018: Dr. Yucai Wang on the Micro-Environment in CLL (chronic lymphocytic leukemia) We have increasingly recognized that it is not enough to only target, but we also need to target where it... July 15, 20192018 ConferencesBy Brad Hedrick
EHA Annual Meeting: Statements from Dr. Koffman For a chance to hear Dr. Koffman’s opinions on 6 quick topics, visit here.... July 9, 20192019 ConferencesBy Brad Hedrick
ASH 2018: Dr. Wang on Richter’s Transformation in CLL (chronic lymphocytic leukemia) Richter’s Transformation (RT) or Richter’s Syndrome (RS) remains a major unmet need in CLL. For a background on RT, please read... June 22, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Davids on The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in CLL (chronic lymphocytic leukemia) At ASH 2018, Dr. Matt Davids from Dana Farber Cancer Institute shared some news on duvelisib, the first dual PI3KƔ... June 17, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Tait Shanafelt on the ECOG-ACRIN Cancer Research Group trial comparing FCR and Ibrutinib/Rituximab in Treatment Naïve CLL (chronic lymphocytic leukemia) of younger patients. By Brian Koffman, MD This is huge. This is game changing. This was one of the six late-breaking abstracts from ASH... June 13, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Nitin Jain on a fixed duration of Ibrutinib and Venetoclax in Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) At ASH 2018, combination therapies were the big buzz, as we discussed in several other interviews (see this recent overview... June 10, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Lindsey Roeker, on real world use of venetoclax for CLL (chronic lymphocytic leukemia) ASH (American Society of Hematology) Annual Conference is a chance for young researchers to present their research to a world... June 3, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. William Wierda MRD Undetectable in CLL (chronic lymphocytic leukemia) Dr. Bill Wierda out of MDACC leads their chronic lymphocytic leukemia team in Houston TX. At ASH 2018 in San Diego,... May 27, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Nicole Lamanna on combination therapies in CLL (chronic lymphocytic leukemia) Dr. Nicole Lamanna of Columbia University Irving Medical Center is a leading CLL researcher who gives us her broad overview... May 20, 20192018 ConferencesBy Brad Hedrick
ASH 2018: Dr. Pete Hillmen on the CLARITY trial of the combination of ibrutinib and venetoclax in relapsed or refractory CLL (chronic lymphocytic leukemia) Dr. Peter Hillmen out of Leeds has developed innovative research techniques to quickly advance the treatment options for CLL patients... May 13, 20192018 ConferencesBy Brad Hedrick
